Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-08-16
2005-08-16
Housel, James (Department: 1648)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C436S023000, C436S023000, C436S023000, C436S024000, C435S320100, C435S325000, C435S235100, C435S236000, C424S186100, C424S189100
Reexamination Certificate
active
06930095
ABSTRACT:
The present invention relates to recombinant hepatitis C virus (HCV)-derived nucleic acids and to stable rapidly growing cell clones derived from human hepatoma Huh-7 cell line and supporting high titer replication of said recombinant HCV nucleic acids. The subgenomic HCV replicons and cell clones of the instant invention represent the in vitro system of choice for studies of HCV propagation, anti-viral drug screening, and vaccine development.
REFERENCES:
patent: 5679342 (1997-10-01), Houghton et al.
patent: 5874565 (1999-02-01), Rice et al.
patent: 6127116 (2000-10-01), Rice et al.
patent: 6392028 (2002-05-01), Rice, III et al.
patent: 6630343 (2003-10-01), Bartenschlager
patent: 6706874 (2004-03-01), Kukolj et al.
patent: 2303526 (2000-10-01), None
patent: WO 98/39031 (1998-09-01), None
Sequence search report.
Blight et al., Science, 2000;290:1972-1974.
Marshall, Eliot, Science, 2000;290:1870-1871.
Lohmann et al., J. Virology, 2001;75(3):1437-1449.
Bartenschlager, J. Viral Hepatitis, 1999, 6:165-181.
Bartenschlager and Lohmann, J. Gen. Virol., 2000, 81:1631-1648.
Baumert et al. J. Virol., 1998, 72(5):3827-3836.
Baumert et al., Gastroenterology, 1999, 117:1397-1407.
Beard et al., Hepatology, 1999, 30:316-324.
Behrens et al., J. Virol., 1998, 72:2364-2372.
Blight and Gowans, Viral Hepatitis Rev., 1995, 1:143-155.
Bouffard et al., J. Infect. Diseases, 1992, 166:1276-1280.
Boyer et al., Virology, 1994; 198:415-426.
Bukh et al., Seminars in Liver Disease, 1995; 15(1):41-63.
Bukh et al., Clin. and Exp. Rheumatol., 1995; 13(Suppl. 13):S3-S7.
Darai et al., J. Infect. Dis., 1978, 137:221-226.
Dash et al., Am. J. Pathol., 1997, 151(2):363-373.
Fournier et al., J. Gen. Virol., 1998, 79:2367-2374.
Iacovacci et al., Res. Virol., 1993, 144:275-279.
Ikeda et al., Virus Res., 1998, 56:157-167.
Ilan et al., Hepatology, 1999, 29:553-562.
Kato et al., Jpn. J. Cancer Res., 1996, 87:787-792.
Khromykh and Westaway, J. Virol., 1997, 71:1497-1505.
Kohara M., J. Dermatol. Sci., 2000, 22:161-168.
Kolykhalov et al., J. Virol., 1996, 70(6):3363-3371.
Kolykhalov et al., Science, 1997, 277:570-574.
Kolykhalov et al., J. Virol., 2000, 74(4):2046-2051.
Lanford et al., 1994, Virology, 202:606-614.
Lieber et al., Journal of Virology, 1996; 70(12):8782-8791.
Liljeström and Garoff, Biotechnol., 1991, 9:1356-1361.
Lohmann et al. Science, 1999, 285:110-113.
Mizutani et al., J. Virol., 1996, 70:7219-7223.
Moormann et al., J. Virol., 1996; 70(2):763-770.
Moradpour et al., Biochem. Biophys. Res. Comm., 1998, 246:920-924.
Müller et al., J. Gen. Virol., 1993, 74:669-676.
Nakabayashi et al., Cancer Res., 1982; 42:3858-3863.
Nakajima et al., J. Virol., 1996, 70(5):3325-3329.
Petersen et al., Proc. Natl. Acad. Sci. USA, 1998, 95:310-315.
Pileri et al., Science, 1998; 282:938-941.
Rosen and Gretch, Mol. Medicine Today, 1999, 5: 393-399.
Ruiz et al., J. Viral Hepatitis, 1999; 6:17-34.
Rumin et al., J. Gen. Virol., 1999, 80:3007-3018.
Shimizu et al., Proc. Natl. Acad. Sci. USA, 1992, 89:5477-5481.
Shimizu and Yoshikura, J. Virol., 1994, 68(12):8406-8408.
Seipp et al., J. Gen. Virol., 1997; 78:2467-2476.
Sugiyama et al., J. Gen. Virol., 1997, 78:329-336.
Tanaka et al., Biochem. Biophys. Res. Comm., 1995, 215(2):744-749.
Tanaka et al., J. Virol., 1996, 70(5):3307-3312.
Walter et al., Hepatology, 1996, 24:1-5.
Xie et al., Virology, 1998, 244:513-520.
Yamada et al.,Virology, 1996, 223:255-261.
Yan et al., J.Cancer Res. Clin. Oncol., 1996, 122:283-288.
Yan et al., J.Cancer Res. Clin. Oncol., 1996, 122:289-295.
Yanagi et al., Proc. Natl. Acad. Sci. USA, 1997, 94:8738-8743.
Yanagi et al., Virology, 1998, 244:161-172.
Yanagi et al., Proc. Natl. Acad. Sci. USA, 1999; 96:2291-2295.
Yoo et al. J. Virol., 1995, 69:32-38.
Zignego et al., J. Hepatol., 1992, 15:382-386.
Anadys Pharmaceuticals, Inc.
Darby & Darby
Housel James
Li Bao Qun
LandOfFree
Hepatitis C virus constructs characterized by high... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hepatitis C virus constructs characterized by high..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hepatitis C virus constructs characterized by high... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3450142